Molecular pathogenesis of cigarette smoking-induced stable COPD

Annals of the New York Academy of Sciences

Volumn 1340, Issue 1, 2015, Pages 55-64

  Caramori, Gaetano ^a   Kirkham, Paul ^b   Barczyk, Adam ^c   Di Stefano, Antonino ^d   Adcock, Ian ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d IRCCS   (Italy)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway inflammation; Autoimmunity; Lymphocytes; Macrophages; Pulmonary pharmacology; Transcription factors

Indexed keywords

CHEMOKINE; CYTOKINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; AUTACOID;

ARTICLE; AUTOIMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; MEDIATOR RELEASE; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOKING; STEM CELL; ADVERSE EFFECTS; ANIMAL; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; HUMANS; INFLAMMATION MEDIATORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84926221026     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12619     Document Type: Article

References (50)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. NIH Publication No 2701A. http://www.goldcopd.com/ (accessed 28 August 2014).
2. Diaz-Guzman, E. & D. Mannino. 2014. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin. Chest. Med. 35: 7-16.
3. Gnatiuc, L. & G. Caramori. 2014. COPD in nonsmokers: the biomass hypothesis-to be or not to be? Eur. Respir. J. 44: 8-10.
4. Fletcher, C. & R. Peto. 1977. The natural history of chronic airflow obstruction. Br. Med. J. 1: 1645-1648.
5. Hobbs, B.D. & C.P. Hersh. 2014. Integrative genomics of chronic obstructive pulmonary disease. Biochem. Biophys. Res. Commun. 452: 276-286.
6. Silverman, E.K. & R.A. Sandhaus. 2009. Clinical practice. Alpha1-antitrypsin deficiency. N. Engl. J. Med. 360: 2749-2757.
7. Kamil, F., I., Pinzon & G.A. Foreman. 2013. Sex and race factors in early-onset COPD. Curr. Opin. Pulm. Med. 19: 140-144.
8. Tam, A. & D.D. Sin. 2013. Why are women more vulnerable to chronic obstructive pulmonary disease? Expert. Rev. Respir. Med. 7: 197-199.
9. Townsend, E.A., V.M., Miller & Y.S. Prakash. 2012. Sex differences and sex steroids in lung health and disease. Endocr. Rev. 33: 1-47.
10. Barnes, P.J. 2004. Small airways in COPD. N. Engl. J. Med. 350: 2635-2637.
11. Hogg, J.C. 2004. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364: 709-721.
12. Caramori, G., P. Casolari, S. Giuffrè, et al. 2011. COPD pathology in the small airways. Panminerva Med. 53: 51-70.
13. McDonough, J.E., R. Yuan, M. Suzuki, et al. 2011. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365: 1567-1575.
14. D'Anna, S.E., R. Asnaghi, G. Caramori, et al. 2012. High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. Respiration 83: 383-390.
15. Galbán, C.J., M.K. Han, J.L. Boes, et al. 2012. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat. Med. 18: 1711-1715.
16. Barnes, P.J. 2014. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest. Med. 35: 71-86.
17. Caramori, G., A. Pandit & A. Papi. 2005. Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease? Curr. Opin. Allergy Clin. Immunol. 5: 77-83.
18. Di Stefano, A., G. Caramori, F.L.M. Ricciardolo, et al. 2004. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin. Exp. Allergy 34: 1156-1167.
19. Hogg, J.C., F. Chu, S. Utokaparch, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350: 2645-2653.
20. Di Stefano, A., G. Caramori, A. Barczyk, et al. 2014. Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax 69: 516-524.
21. Barczyk, A., W. Pierzchala, O.M. Kon, et al. 2006. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 117: 1484-1492.
22. Di Stefano, A., G. Caramori, I. Gnemmi, et al. 2009. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin. Exp. Immunol. 157: 316-324.
23. Cappello, F., G. Caramori, C. Campanella, et al. 2011. Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis. PLoS One 6: e28200-e28211.
24. Caramori, G., A. Di Stefano, P. Casolari, et al. 2013. Chemokines And chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease. Curr. Med. Chem. 20: 4317-4349.
25. Caramori, G., I.M. Adcock, A. Di Stefano & K.F. Chung. 2014. Cytokine inhibition in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 9: 397-412.
26. Xue, J., S.V. Schmidt, J. Sander, et al. 2014. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40: 274-88.
27. Holloway, R.A. & L.E. Donnelly. 2013. Immunopathogenesis of chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 19: 95-102.
28. Ricciardolo, F.L.M., G. Caramori, K. Ito, et al. 2005. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 116: 1028-1035.
29. Meijer, M., G.T. Rijkers & F.J. van Overveld. 2013. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert. Rev. Clin. Immunol. 9: 1055-1068.
30. Adcock, I.M., G. Caramori & P.A. Kirkham. 2012. Strategies for improving the efficacy and therapeutic ratio of glucocorticoids. Curr. Opin. Pharmacol. 12: 246-251.
31. Anthonisen, N.R., M.A. Skeans, R.A. Wise, et al. 2005. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142: 233-239.
32. Adcock, I.M., G. Caramori & P.J. Barnes. 2011. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 81: 265-284.
33. Caramori, G., P. Casolari, G.N. Cavallesco, et al. 2011. Mechanisms involved in lung cancer development in COPD. Int. J. Biochem. Cell Biol. 43: 1030-1044.
34. Caramori, G., P. Casolari, E. Garofano, et al. 2012. Role of stem cells in the pathogenesis of COPD and pulmonary emphysema. In Stem Cells and Cancer Stem Cells, Volume 6. Therapeutic Applications in Disease and Injury Series. M.A. Hayat, Ed.: 307-317. Dordrecht, the Netherlands: Springer.
35. Barnes, P.J. 2001. Neurogenic inflammation in the airways. Respir. Physiol. 125: 145-154.
36. Kirkham, P.A. & P.J. Barnes. 2013. Oxidative stress in COPD. Chest 144: 266-273.
37. Caramori, G., P. Casolari & I. Adcock. 2013. Role of transcription factors in the pathogenesis of asthma and COPD. Cell Commun. Adhes. 20: 21-40.
38. Papi, A., M. Chicca, A. Pandit & G. Caramori. 2006. Oxidants and antioxidants. Antioxidants, nonenzymatic. In Encyclopedia of Respiratory Medicine. Geoffrey J. Laurent and Steven D. Shapiro, Eds.: 266-271. London, UK: Elsevier.
39. Psarras, S., G. Caramori, M. Contoli, et al. 2005. Oxidants in asthma and in chronic obstructive pulmonary disease (COPD). Curr. Pharm. Des. 11: 2053-2062.
40. Caramori, G., I.M. Adcock, P. Casolari, et al. 2011. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 66: 521-527.
41. Gross, N.J., E. Co & M.S. Skorodin. 1989. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 96: 984-987.
42. Barnes, P.J. 2004. Distribution of receptor targets in the lung. Proc. Am. Thor. Soc. 1: 345-351.
43. Pieper, M.P. 2012. The non-neuronal cholinergic system as novel drug target in the airways. Life Sci. 91: 1113-1118.
44. Profita, M., Bonanno, A., Montalbano, A.M., et al. 2012. β2 long-acting and anticholinergic drugs control TGF-β-mediated neutrophilic inflammation in COPD. Biochim. Biophys. Acta. 1822: 1079-1089.
45. Profita, M., Albano, G.D., Riccobono, L., et al. 2014. Increased levels of Th17 cells are associated with non-neuronal acetylcholine in COPD patients. Immunobiology 219: 392-401.
46. Kirkham, P.A., G. Caramori, P. Casolari, et al. 2011. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 184: 796-802.
47. Hogg, J.C. & W. Timens. 2009. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4: 435-459.
48. Adcock, I.M., J. Marwick, P. Casolari, et al. 2010. Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD). Curr. Pharm. Des. 16: 3554-3573.
49. Marwick, J.A., G. Caramori, P. Casolari, et al. 2010. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 125: 1146-1153.
50. Ford, P.A., A.L. Durham, R.E. Russell, et al. 2010. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137: 1338-1344.